#59117

Why It Matters

The adjustment locks in a predictable cash component for option holders, simplifying settlement and reducing exposure to volatile SCYX price swings during the corporate event window.

Key Takeaways

• OCC adjusted SCYX1 options to deliver 12 shares plus $2.85 cash.
• Cash‑in‑lieu calculated using $5.6936 per SCYX share.
• Settlement window runs June 1‑5, 2026; cash handled by OCC.
• Underlying SCYX1 price formula: 0.12×SCYX + 0.0285.
• Fixed cash amount stays unchanged despite SCYX price swings.

Pulse Analysis

The Options Clearing Corporation’s recent adjustment to SCYNEXIS (SCYX) options underscores how clearing houses manage corporate events to preserve market integrity. By converting fractional share entitlements into a cash‑in‑lieu payment of $2.85 per contract, OCC eliminates the logistical challenges of delivering half‑shares while providing a transparent, dollar‑based settlement. This approach aligns with OCC’s rulebook, which mandates case‑by‑case adjustments to ensure that option contracts remain economically equivalent after a corporate action.

For traders and institutional investors, the fixed cash component offers a predictable cost basis, regardless of SCYX’s price volatility during the June 1‑5, 2026 window. The underlying SCYX1 option price will be derived from the formula 0.12 × SCYX + 0.0285, meaning that while the equity portion fluctuates with market movements, the cash element remains static. This separation simplifies hedging strategies, as participants can isolate equity exposure from cash risk, and it reduces the potential for settlement mismatches that could arise from rapid price swings.

The broader market impact reflects OCC’s role in maintaining orderly options trading amid corporate restructurings. By clearly communicating the new deliverable—12 shares plus $2.85 cash—and outlining settlement procedures through the NSCC and OCC, the memo helps clearing members and market participants adjust their positions efficiently. Such transparency supports liquidity, mitigates operational risk, and reinforces confidence in the options ecosystem, especially for biotech firms like SCYNEXIS where stock price volatility is common.